BioSpace News Archive

Nutrition Reviews® published a systematic review and meta-analysis of 18 controlled intervention studies on the effectiveness of omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) in patients with non-alcoholic fatty liver disease (NAFLD).

Also in This Edition: Jobs for Writers, Media Industry News

FIGS is proud to be recognized as No. 21 on Inc. Magazine’s Inc. 5000 ranking of the nation’s fastest-growing private companies.

Audacious Inquiry now has several statewide deployments with NextGate’s Enterprise Master Patient Index (EMPI) to support offering a full range of health information exchange solutions, building on Ai’s high-value Encounter Notification Service® (ENS®).

ViewRay, Inc. announced the completion of its previously announced underwritten public offering of 18,648,649 shares of common stock at a price to the public of $9.25 per share

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Flex Pharma, Inc. between November 6, 2017 and June 12, 2018, both dates inclusive (the “Class Period”).

The American Association of Kidney Patients (AAKP), the nation’s oldest and largest, fully independent kidney patient organization announced plans to join patient research efforts for The Kidney Project

Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of the scrip dividend elections.

The biopharmaceutical company MOLOGEN AG yesterday signed, with the consent of the Supervisory Board, a term sheet outlining the framework for a global assignment of all intellectual property and other rights in MOLOGEN’s lead compound lefitolimod to ONCOLOGIE and an expansion of the existing global co-development agreement between MOLOGEN and ONCOLOGIE.

ClaimsFiler reminds investors that they have until September 17, 2018 to file lead plaintiff applications in a securities class action lawsuit against ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD), if they purchased the Company’s securities between April 29, 2016 and July 9, 2018